Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$1.10
$1.21
$0.84
$2.03
$41.94M1.0594,305 shs38,139 shs
CZX
Canada Zinc Metals
C$0.31
+∞
C$0.31
C$0.22
C$0.39
C$51.69MN/A238,645 shs118,500 shs
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$20.86
C$18.60
C$22.79
N/AN/A468,009 shs3.04 million shs
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
$14.72
$0.00
$8.30
$20.25
N/AN/A2.83 million shsN/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.00%-0.90%-18.52%0.00%-32.93%
CZX
Canada Zinc Metals
0.00%0.00%0.00%0.00%0.00%
First Capital Realty Inc. stock logo
FCR
First Capital Realty
0.00%0.00%0.00%0.00%0.00%
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.092 of 5 stars
3.50.00.00.01.73.31.3
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/AN/AN/A
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.00
Buy$7.00536.36% Upside
CZX
Canada Zinc Metals
N/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/A
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/AN/AN/A

Current Analyst Ratings

Latest MRD, BOLT, CZX, and FCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.88M5.33N/AN/A$2.97 per share0.37
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/A
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$69.20M-$1.83N/AN/AN/A-878.58%-51.18%-37.81%5/9/2024 (Estimated)
CZX
Canada Zinc Metals
N/AN/A0.00N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/A0.00N/AN/AN/AN/AN/A8/6/2024 (Estimated)
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/A0.00N/AN/AN/AN/AN/A

Latest MRD, BOLT, CZX, and FCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$0.47-$0.47N/A-$0.47$1.97 million$2.09 million
2/6/2024Q4 2023
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.31C$0.81+C$0.50C$0.81N/AC$171.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$0.3632.73%N/AN/A N/A
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/A
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/AN/AN/AN/A

Latest MRD, BOLT, CZX, and FCR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.074.14%4/29/20244/30/20245/15/2024
3/15/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.073/27/20243/28/20244/15/2024
2/6/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.072/28/20242/29/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.15
5.17
5.17
CZX
Canada Zinc Metals
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/A
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/AN/A

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
10038.13 million27.30 millionNot Optionable
CZX
Canada Zinc Metals
147,000166.73 millionN/ANot Optionable
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/ANot Optionable
Memorial Resource Development Corp stock logo
MRD
Memorial Resource Development
N/AN/AN/ANot Optionable

MRD, BOLT, CZX, and FCR Headlines

SourceHeadline
Resource development trainingResource development training
helpage.org - April 21 at 8:25 PM
FDA Advisors Unanimously Support Using MRD to Expedite Multiple Myeloma Drugs Through TrialsFDA Advisors Unanimously Support Using MRD to Expedite Multiple Myeloma Drugs Through Trials
precisionmedicineonline.com - April 14 at 9:36 PM
FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma TrialsFDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
targetedonc.com - April 13 at 12:26 AM
Orlando gives update on Pulse memorial projectOrlando gives update on Pulse memorial project
orlandoweekly.com - April 10 at 12:37 AM
The Jefferson City Council Has Approved The Final Reading, Effectively Rezoning The Area For New Proposed KCG DevelopmentThe Jefferson City Council Has Approved The Final Reading, Effectively Rezoning The Area For New Proposed KCG Development
1380kcim.com - March 14 at 8:06 PM
Memorial Day target date for Brickway of History completionMemorial Day target date for Brickway of History completion
starexponent.com - March 12 at 6:53 PM
Learning and developmentLearning and development
unr.edu - December 20 at 1:33 AM
MRD Negativity May Be Achievable With Revumenib in Some Leukemia SubsetMRD Negativity May Be Achievable With Revumenib in Some Leukemia Subset
curetoday.com - December 12 at 6:47 PM
MSc Human Resource Development (International Development)MSc Human Resource Development (International Development)
manchester.ac.uk - December 9 at 6:10 PM
MPG & JAAS Discuss Potential Areas Of Cooperation For Agriculture DevelopmentMPG & JAAS Discuss Potential Areas Of Cooperation For Agriculture Development
scoop.co.nz - November 6 at 8:49 AM
Central Mass. receives $28M in state economic development money for 55 projectsCentral Mass. receives $28M in state economic development money for 55 projects
wbjournal.com - October 30 at 12:41 AM
Faculty DevelopmentFaculty Development
slu.edu - October 27 at 8:27 PM
Transition Underway at Torrance MemorialTransition Underway at Torrance Memorial
labusinessjournal.com - October 10 at 10:31 AM
R.I. Attorney General is filing a motion to intervene on Memorial Hospital developmentR.I. Attorney General is filing a motion to intervene on Memorial Hospital development
bostonglobe.com - April 4 at 2:14 AM
In sAML, Does MRD Status Before Allogeneic HCT Affect Outcome?In sAML, Does MRD Status Before Allogeneic HCT Affect Outcome?
medpagetoday.com - March 18 at 10:33 PM
15 Top Memorial Day Weekend Getaways15 Top Memorial Day Weekend Getaways
travel.usnews.com - March 15 at 11:27 PM
IMUNON CEO Issues Letter to ShareholdersIMUNON CEO Issues Letter to Shareholders
it.tmcnet.com - March 1 at 11:32 AM
Detectable MRD Is Prognostic of Poor HCT Outcomes in Adult ALLDetectable MRD Is Prognostic of Poor HCT Outcomes in Adult ALL
targetedonc.com - February 17 at 1:19 PM
President stresses on investing in human resource for GB developmentPresident stresses on investing in human resource for GB development
radio.gov.pk - February 13 at 10:53 PM
Plan for Federal AI Research and Development Resource Emphasizes Diversity in InnovationPlan for Federal AI Research and Development Resource Emphasizes Diversity in Innovation
nextgov.com - January 27 at 8:13 PM
Ace of Trades: Tierney Ford is the resource development director for United WayAce of Trades: Tierney Ford is the resource development director for United Way
zanesvilletimesrecorder.com - October 8 at 12:46 AM
Memorial Resource Stands Out in Depressed Oil and Gas SectorMemorial Resource Stands Out in Depressed Oil and Gas Sector
thestreet.com - September 8 at 9:55 PM
Memorial Resource (MRD) Stock Spikes, Range Resources to AcquireMemorial Resource (MRD) Stock Spikes, Range Resources to Acquire
thestreet.com - September 2 at 10:15 PM
Preview: Trijicon Dual Defense KitPreview: Trijicon Dual Defense Kit
americanrifleman.org - August 24 at 11:49 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bolt Biotherapeutics logo

Bolt Biotherapeutics

NASDAQ:BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Canada Zinc Metals

CVE:CZX
Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.
First Capital Realty logo

First Capital Realty

TSE:FCR
Memorial Resource Development logo

Memorial Resource Development

NASDAQ:MRD
Range Resources-Louisiana, Inc., formerly Memorial Resource Development Corp, is an independent natural gas and oil company focused on the acquisition, exploration and development of natural gas and oil properties with substantially all of its activities in the Terryville Complex of North Louisiana. The Company's segments include MRD and Memorial Production Partners LP (MEMP). The MRD Segment is focused on the acquisition, exploration, and development of natural gas and oil properties primarily in the Cotton Valley formation in North Louisiana. The MEMP Segment is engaged in the acquisition, exploitation, development and production of oil and natural gas properties, with assets consisting primarily of producing oil and natural gas properties that are located in Texas, Louisiana, Colorado, Wyoming and offshore Southern California. The MEMP segment reflects the combined operations of MEMP and its subsidiaries.